Metabolic Tumor Volume Predicts Overall Survival in Patients with Primary Pulmonary Lymphoepithelioma-like Carcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Dec 3

PMID 31788088

Citations 2

Authors

Chun-Yu Lin

Yu-Chuan Chang

I-Ting Wang

Meng-Heng Hsieh

Chih-Wei Wang

Shu-Min Lin

Ching-Yang Wu

Yueh-Fu Fang

Affiliations

Soon will be listed here.

Abstract

Pretreatment tumor metabolic burden, measured using fluorine-18 fluorodeoxyglucose positron emission tomography/computerized tomography (F-FDG PET/CT), has been demonstrated to predict outcomes in various types of malignancies. Additionally, Epstein-Barr virus (EBV) serum titer is associated with stages of pulmonary lymphoepithelioma-like carcinoma (LELC). The present study aimed to investigate the prognostic value of the functional parameters of F-FDG PET/CT in pulmonary LELC and their association with serum EBV DNA. The present retrospective study analyzed data from 71 patients with pulmonary LELC; among these, 32 patients with pulmonary LELC underwent pretreatment F-FDG PET/CT staging between January 2008 and December 2016. EBV viral load and functional parameters of F-FDG PET/CT were used for survival analysis. Multivariate analysis identified tumor stage IV as a significant predictor of poor progression-free survival [hazard ratio (HR), 4.85; P=0.049], whereas elevated total metabolic tumor volume (MTV ≥72.6 ml) independently predicted worse overall survival (OS; HR, 12.59; P=0.024). Pretreatment serum EBV DNA titer was significantly positively associated with total MTV (P=0.0337) and total lesion glycolysis (TLG; P=0.0093), but could not predict outcomes. Total MTV was an independent predictor of OS, and may guide clinical management for pulmonary LELC.

Citing Articles

Epidemiology and prognosis of lymphoepithelioma-like carcinoma: a comprehensive analysis of surveillance, epidemiology, and end results (SEER) database.

Qi W, Zhao S, Chen J Int J Clin Oncol. 2021; 26(7):1203-1211.

PMID: 33844112 DOI: 10.1007/s10147-021-01921-z.

The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis.

Tang L, Chen N, He W, Zhou J, Zhang J, Lin Z PLoS One. 2020; 15(10):e0240729.

PMID: 33064745 PMC: 7567369. DOI: 10.1371/journal.pone.0240729.

References

Ngan R, Yip T, Cheng W, Chan J, Cho W, Ma V . Clinical role of circulating Epstein-Barr virus DNA as a tumor marker in lymphoepithelioma-like carcinoma of the lung. Ann N Y Acad Sci. 2004; 1022:263-70. DOI: 10.1196/annals.1318.041. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Liu J, Dong M, Sun X, Li W, Xing L, Yu J . Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS One. 2016; 11(1):e0146195. PMC: 4699812. DOI: 10.1371/journal.pone.0146195. View

Shen T, Tang L, Luo D, Chen Q, Li P, Mai D . Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence. PLoS One. 2015; 10(4):e0122756. PMC: 4390333. DOI: 10.1371/journal.pone.0122756. View

Chang Y, Wu C, Shih J, Lee Y . New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am J Surg Pathol. 2002; 26(6):715-23. DOI: 10.1097/00000478-200206000-00004. View

Hung C, Lin T, Kuo Y, Hsieh C, Wang H, Hsu C . Progesterone analogues reduce plasma Epstein-Barr virus DNA load and improve pain control in recurrent/metastatic nasopharyngeal carcinoma patients under supportive care. Biomed J. 2017; 40(4):212-218. PMC: 6136283. DOI: 10.1016/j.bj.2017.06.006. View

Liang Y, Wang L, Zhu Y, Lin Y, Liu H, Rao H . Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up. Cancer. 2012; 118(19):4748-58. DOI: 10.1002/cncr.27452. View

Su T, Ho K, Wang C, Lin C, Liu C, Yang C . Prognostic Value and Clinical Impact of Pretreatment FDG PET in Pulmonary Lymphoepithelioma-Like Carcinoma. Clin Nucl Med. 2019; 44(2):e68-e75. DOI: 10.1097/RLU.0000000000002371. View

Hayashi T, Haba R, Tanizawa J, Katsuki N, Kadota K, Miyai Y . Cytopathologic features and differential diagnostic considerations of primary lymphoepithelioma-like carcinoma of the lung. Diagn Cytopathol. 2011; 40(9):820-5. DOI: 10.1002/dc.21670. View

10.

Obara P, Pu Y . Prognostic value of metabolic tumor burden in lung cancer. Chin J Cancer Res. 2014; 25(6):615-22. PMC: 3872558. DOI: 10.3978/j.issn.1000-9604.2013.11.10. View

11.

Adams M, Turkington T, Wilson J, Wong T . A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010; 195(2):310-20. DOI: 10.2214/AJR.10.4923. View

12.

Chung H, Lee K, Kim H, Kim W, So Y . FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. J Cancer Res Clin Oncol. 2013; 140(1):89-98. DOI: 10.1007/s00432-013-1545-7. View

13.

Ege Aktas G, Can N, Demir S, Sarikaya A . Primary Pulmonary Lymphoepithelioma-like Carcinoma on FDG PET/CT. Nucl Med Mol Imaging. 2017; 51(1):88-92. PMC: 5313461. DOI: 10.1007/s13139-016-0428-7. View

14.

Beasley M, Brambilla E, Travis W . The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005; 40(2):90-7. DOI: 10.1053/j.ro.2005.01.001. View

15.

Lv Y, Yuan D, Wang K, Miao X, Qian Q, Wei S . Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol. 2011; 6(8):1350-8. DOI: 10.1097/JTO.0b013e31821d4384. View

16.

Han A, Xiong M, Zong Y . Association of Epstein-Barr virus with lymphoepithelioma-like carcinoma of the lung in southern China. Am J Clin Pathol. 2000; 114(2):220-6. DOI: 10.1309/148K-ND54-6NJX-NA61. View

17.

Zhang W, Chen Y, Chen L, Guo R, Zhou G, Tang L . The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases. Medicine (Baltimore). 2015; 94(20):e845. PMC: 4602858. DOI: 10.1097/MD.0000000000000845. View

18.

Gu J, Khong P, Wang S, Chan Q, Law W, Zhang J . Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT. Mol Imaging Biol. 2010; 13(5):1020-8. PMC: 3179585. DOI: 10.1007/s11307-010-0433-7. View

19.

Hsu C, Chang K, Lin C, Chang H, Wang C, Lin T . Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck. 2011; 34(8):1064-70. DOI: 10.1002/hed.21890. View

20.

Lee P, Bazan J, Lavori P, Weerasuriya D, Quon A, Le Q . Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer. 2011; 13(1):52-58. PMC: 4296977. DOI: 10.1016/j.cllc.2011.05.001. View